Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28175073 | 0.99 | ADRB2 (0.53) | ADRB2NCF1KCNH2PDGFRBDRD2 | |
| SCHEMBL28661982 | 0.85 | ADRB2 (0.58) | ADRB2NCF1KCNH2PDGFRBDRD2 | |
| Hydrochloric Acid SCHEMBL28250642 | 0.84 | ADRB2 (0.57) | ADRB2NCF1KCNH2PDGFRBDRD2 | |
| SCHEMBL21173533 | 0.81 | CKS1B (0.56) | ADRB2NCF1PDGFRBDRD2 | |
| SCHEMBL22755427 | 0.80 | ADRB2 (0.63) | ADRB2NCF1KCNH2PDGFRBCNR2 | |
| SCHEMBL28284091 | 0.79 | NCF1 (0.45) | ADRB2NCF1 | |
| SCHEMBL28250634 | 0.79 | ADRB2 (0.51) | ADRB2NCF1KCNH2PDGFRBDRD2 | |
| SCHEMBL27666031 | 0.79 | ADRB2 (0.51) | ADRB2NCF1KCNH2PDGFRB | |
| SCHEMBL16096541 | 0.78 | KDM4E (0.61) | NCF1HTTSMN1; SMN2 | |
| SCHEMBL4018098 | 0.77 | NCF1 (0.63) | ADRB2NCF1KCNH2PDGFRBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | claimed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| CN-109415343-A | For treating substituted 2,4- diamino-quinoline of proliferative diseases | 基因科学医药公司 | 2019-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | ADRB2 831/4885NCF1 1781/4885KCNH2 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.